I'm afraid I disagree with CVP in that it's not «unwillingness of FDA officials to spend the time it takes to understand the products,» but rather they're spending time in a concerted effort with other ANTZ, BP, and quite possibly BT, to manufacture an image of the products in such way that it aligns with FDA's predetermined position. Elsewhere, CVP does mention that «this process was not about seeking the truth, but rather creating the truth.»
On another topic, it's interesting that the last article in the series actually provides a token citation for the Burstyn study, but uses it in the weakest possible way, to highlight potential methodological problems in ecig and vapor studies. Not a single mention of the Burstyn conclusions is discussed. I say interesting, because I expected the Burstyn study would not be mentioned by any of the articles, all of which are by FDA/CTP staff. Several studies by Farsalinos are also cited in the other articles in the series, also without mentioning any of the positive findings of that research.